SetPoint Medical previously announced the primary efficacy endpoint of ACR20 response was met in the RESET-RA study, which enrolled 242 participants. An ACR20 response is a composite measure of the ...
A team led by Mass General Brigham researchers demonstrated that inebilizumab reduced the risk of symptoms by 87% in patients with the rare affliction known as immunoglobulin G4–related disease (IgG4- ...